Departamento de Microbiología, Medicina Preventiva y Salud Pública, Universidad de Zaragoza, Zaragoza, Spain.
Centro Nacional de Biotecnología, CSIC, Darwin 3, Madrid, Spain.
Nat Rev Microbiol. 2023 Oct;21(10):671-685. doi: 10.1038/s41579-023-00902-5. Epub 2023 May 19.
Antibiotic resistance is currently one of the most important public health problems. The golden age of antibiotic discovery ended decades ago, and new approaches are urgently needed. Therefore, preserving the efficacy of the antibiotics currently in use and developing compounds and strategies that specifically target antibiotic-resistant pathogens is critical. The identification of robust trends of antibiotic resistance evolution and of its associated trade-offs, such as collateral sensitivity or fitness costs, is invaluable for the design of rational evolution-based, ecology-based treatment approaches. In this Review, we discuss these evolutionary trade-offs and how such knowledge can aid in informing combination or alternating antibiotic therapies against bacterial infections. In addition, we discuss how targeting bacterial metabolism can enhance drug activity and impair antibiotic resistance evolution. Finally, we explore how an improved understanding of the original physiological function of antibiotic resistance determinants, which have evolved to reach clinical resistance after a process of historical contingency, may help to tackle antibiotic resistance.
抗生素耐药性是当前最重要的公共卫生问题之一。抗生素的发现黄金时代在几十年前就已经结束,现在急需新的方法。因此,保留当前使用的抗生素的疗效,并开发专门针对抗药性病原体的化合物和策略至关重要。确定抗生素耐药性进化的稳健趋势及其相关的权衡,例如附带敏感性或适应性成本,对于设计基于理性进化和基于生态学的治疗方法是非常宝贵的。在这篇综述中,我们讨论了这些进化权衡,以及这些知识如何有助于为针对细菌感染的联合或交替抗生素治疗提供信息。此外,我们还讨论了如何靶向细菌代谢来增强药物活性和削弱抗生素耐药性进化。最后,我们探讨了如何通过提高对抗生素耐药性决定因素的原始生理功能的理解,这些决定因素在经过历史偶然的过程后才达到临床耐药性,从而有助于解决抗生素耐药性问题。